{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:48:13Z","timestamp":1793828893075,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["contract 75N910D00024, task order 75N91022F00007"],"award-info":[{"award-number":["contract 75N910D00024, task order 75N91022F00007"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["contract 75N910D00024, task order no. 75N91022F00007"],"award-info":[{"award-number":["contract 75N910D00024, task order no. 75N91022F00007"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00012"],"award-info":[{"award-number":["75N93021C00012"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI148684"],"award-info":[{"award-number":["UM1AI148684"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["Contract no. 75A50122C00008"],"award-info":[{"award-number":["Contract no. 75A50122C00008"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50122C00008"],"award-info":[{"award-number":["75A50122C00008"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75N93021D00021"],"award-info":[{"award-number":["75N93021D00021"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005370","name":"Gates Cambridge Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic\u2019s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate\u2019s contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and\/or Omicron BA.1 or BA.4\/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 (\u201cCOVID-19\u201d) and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. Consistently across the Moderna and Pfizer-BioNTech vaccine platforms and across all variant Spike inserts assessed, both peak and exposure-proximal (\u201cpredicted-at-exposure\u201d) titers correlated with lower Omicron COVID-19 risk in individuals previously infected with SARS-CoV-2, albeit significantly less so in na\u00efve individuals [e.g., exposure-proximal hazard ratio per 10-fold increase in BA.1 titer 0.74 (95% CI 0.59, 0.94) for na\u00efve vs. 0.41 (95% CI 0.23, 0.64) for non-na\u00efve; interaction p\u2009=\u20090.013]. Neutralizing antibody titer was a strong inverse correlate of Omicron COVID-19 in non-na\u00efve individuals and a weaker correlate in na\u00efve individuals, posing questions about how prior infection alters the neutralization correlate.<\/jats:p>","DOI":"10.1038\/s41467-025-55931-w","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:53:50Z","timestamp":1737086030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-1124","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fintzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2902-0403","authenticated-orcid":false,"given":"Shiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-7919","authenticated-orcid":false,"given":"Nadine G.","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-5352","authenticated-orcid":false,"given":"Angela R.","family":"Branche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2789-0512","authenticated-orcid":false,"given":"David J.","family":"Diemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann R.","family":"Falsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-8488","authenticated-orcid":false,"given":"Daniel S.","family":"Graciaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1752-1926","authenticated-orcid":false,"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-9737","authenticated-orcid":false,"given":"Susan J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-1217","authenticated-orcid":false,"given":"Richard","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-2664","authenticated-orcid":false,"given":"Craig A.","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Molitor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-8343","authenticated-orcid":false,"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-2382","authenticated-orcid":false,"given":"Antonia","family":"Netzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-1890","authenticated-orcid":false,"given":"Derek J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-1666","authenticated-orcid":false,"given":"Angelica C.","family":"Kottkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-1578","authenticated-orcid":false,"given":"Anne F.","family":"Luetkemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly C.","family":"Immergluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"B\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Winokur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham M.","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-5737","authenticated-orcid":false,"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0110","authenticated-orcid":false,"given":"Dahlene N.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-6772","authenticated-orcid":false,"given":"Robert L.","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Posavad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjian","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat","family":"Makowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamodikoe K.","family":"Makhene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema U.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-141X","authenticated-orcid":false,"given":"Paul C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-9427","authenticated-orcid":false,"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4073-0393","authenticated-orcid":false,"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"55931_CR1","unstructured":"US Food and Drug Administration. COVID-19 vaccines. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines#authorized-vaccines (2024)."},{"key":"55931_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172\u20131183 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med"},{"key":"55931_CR5","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"55931_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-042921-020956","volume":"74","author":"JL Jacobs","year":"2023","unstructured":"Jacobs, J. L., Haidar, G. & Mellors, J. W. COVID-19: challenges of viral variants. Annu Rev. Med. 74, 31\u201353 (2023).","journal-title":"Annu Rev. Med."},{"key":"55931_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.15585\/mmwr.mm7105e1","volume":"71","author":"P Danza","year":"2022","unstructured":"Danza, P. et al. SARS-CoV-2 infection and hospitalization among adults aged >\/=18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (Omicron) variant predominance - Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb. Mortal. Wkly Rep. 71, 177\u2013181 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"55931_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.15585\/mmwr.mm7104e2","volume":"71","author":"AG Johnson","year":"2022","unstructured":"Johnson, A. G. et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. MMWR Morb. Mortal. Wkly Rep. 71, 132\u2013138 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"55931_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N. Engl. J. Med. 386, 340\u2013350 (2022).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063\u20131071 (2022).","journal-title":"Nat. Med."},{"key":"55931_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-2600(22)00101-1","volume":"10","author":"SY Tartof","year":"2022","unstructured":"Tartof, S. Y. et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir. Med. 10, 689\u2013699 (2022).","journal-title":"Lancet Respir. Med."},{"key":"55931_CR13","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","volume":"385","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 385, e83 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR14","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR15","doi-asserted-by":"publisher","first-page":"1130539","DOI":"10.3389\/fimmu.2023.1130539","volume":"14","author":"S Pather","year":"2023","unstructured":"Pather, S. et al. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front. Immunol. 14, 1130539 (2023).","journal-title":"Front. Immunol."},{"key":"55931_CR16","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) update: FDA recommends inclusion of Omicron BA.4\/5 component for COVID-19 vaccine booster doses. Press Release\/Public Statement. 6\/30\/22. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines."},{"key":"55931_CR17","unstructured":"US Food and Drug Administration. Updated COVID-19 vaccines for use in the United States beginning in fall 2023. Press Release\/Public Statement. 6\/16\/2023. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines."},{"key":"55931_CR18","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","volume":"29","author":"AR Branche","year":"2023","unstructured":"Branche, A. R. et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat. Med. 29, 2334\u20132346 (2023).","journal-title":"Nat. Med."},{"key":"55931_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/cid\/ciad209","volume":"77","author":"AR Branche","year":"2023","unstructured":"Branche, A. R. et al. Immunogenicity of the BA.1 and BA.4\/BA.5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial. Clin. Infect. Dis. 77, 560\u2013564 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"55931_CR20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"55931_CR21","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"55931_CR22","doi-asserted-by":"crossref","unstructured":"Plotkin, S. A. & Gilbert, P. B. Correlates of protection. In Vaccines, 8th edn (eds Orenstein, W., Offit, P., Edwards, K. & Plotkin, S.) 35\u201340 (Elsevier Inc., New York, 2022).","DOI":"10.1016\/B978-0-323-35761-6.00003-1"},{"key":"55931_CR23","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.vaccine.2024.02.071","volume":"42","author":"PB Gilbert","year":"2024","unstructured":"Gilbert, P. B. et al. Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial. Vaccine 42, 2181\u20132190 (2024).","journal-title":"Vaccine"},{"key":"55931_CR24","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1002\/sim.8212","volume":"38","author":"Z He","year":"2019","unstructured":"He, Z. & Fong, Y. Maximum diversity weighting for biomarkers with application in HIV-1 vaccine studies. Stat. Med. 38, 3936\u20133946 (2019).","journal-title":"Stat. Med."},{"key":"55931_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae465","author":"Y Fong","year":"2024","unstructured":"Fong, Y. et al. Neutralizing antibody immune correlates for a recombinant protein vaccine in the COVAIL trial. ciae465. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciae465 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"55931_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxae031","author":"Y Huang","year":"2024","unstructured":"Huang, Y. & Follmann, D. Exposure proximal immune correlates analysis. Biostatistics https:\/\/doi.org\/10.1093\/biostatistics\/kxae031 (2024).","journal-title":"Biostatistics"},{"key":"55931_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"55931_CR28","unstructured":"Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS): coronavirus disease 2019 (COVID-19) 2021 case definition. https:\/\/ndc.services.cdc.gov\/case-definitions\/coronavirus-disease-2019-2021\/ (2021)."},{"key":"55931_CR29","doi-asserted-by":"publisher","unstructured":"Zhang, B. et al. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.10.15.23295628 (2023).","DOI":"10.1101\/2023.10.15.23295628"},{"key":"55931_CR30","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"HM El Sahly","year":"2021","unstructured":"El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N. Engl. J. Med. 385, 1774\u20131785 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR31","doi-asserted-by":"publisher","first-page":"eade9078","DOI":"10.1126\/scitranslmed.ade9078","volume":"15","author":"D Benkeser","year":"2023","unstructured":"Benkeser, D. et al. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci. Transl. Med. 15, eade9078 (2023).","journal-title":"Sci. Transl. Med."},{"key":"55931_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijid.2023.09.012","volume":"137","author":"NS Hejazi","year":"2023","unstructured":"Hejazi, N. S. et al. Stochastic interventional approach to assessing immune correlates of protection: application to the COVE messenger RNA-1273 vaccine trial. Int. J. Infect. Dis. 137, 28\u201339 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"55931_CR33","doi-asserted-by":"publisher","unstructured":"Huang, Y. et al. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial. Viruses https:\/\/doi.org\/10.3390\/v15102029 (2023).","DOI":"10.3390\/v15102029"},{"key":"55931_CR34","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e2413 (2022).","journal-title":"Cell"},{"key":"55931_CR35","unstructured":"Benkeser, D., D\u00edaz, I. & Ran, J. Inference for natural mediation effects under case-cohort sampling with applications in identifying COVID-19 vaccine correlates of protection. Preprint at https:\/\/arxiv.org\/abs\/2103.02643 (2021)."},{"key":"55931_CR36","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMp2211314","volume":"387","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. A Covid-19 milestone attained \u2014 a correlate of protection for vaccines. N. Engl. J. Med. 387, 2203\u20132206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"55931_CR37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"55931_CR38","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"55931_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.13089","volume":"310","author":"A Sette","year":"2022","unstructured":"Sette, A. & Crotty, S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol. Rev. 310, 27\u201346 (2022).","journal-title":"Immunol. Rev."},{"key":"55931_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"55931_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/imm.12861","volume":"153","author":"KB Arnold","year":"2018","unstructured":"Arnold, K. B. & Chung, A. W. Prospects from systems serology research. Immunology 153, 279\u2013289 (2018).","journal-title":"Immunology"},{"key":"55931_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/infdis\/jiab161","volume":"224","author":"JG Petrie","year":"2021","unstructured":"Petrie, J. G. et al. Coronavirus occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: reinfection frequency and serologic responses to seasonal and severe acute respiratory syndrome coronaviruses. J. Infect. Dis. 224, 49\u201359 (2021).","journal-title":"J. Infect. Dis."},{"key":"55931_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00630-0","volume":"8","author":"D Benkeser","year":"2023","unstructured":"Benkeser, D. et al. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. NPJ Vaccines 8, 36 (2023).","journal-title":"NPJ Vaccines"},{"key":"55931_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35768-3","volume":"14","author":"Y Fong","year":"2023","unstructured":"Fong, Y. et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun. 14, 331 (2023).","journal-title":"Nat. Commun."},{"key":"55931_CR45","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Y Fong","year":"2022","unstructured":"Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 7, 1996\u20132010 (2022).","journal-title":"Nat. Microbiol."},{"key":"55931_CR46","unstructured":"Polley, E. C., LeDell, E., Kennedy, C. J. & van der Laan, M. J. SuperLearner: super learner prediction. R package version 2.0-28. https:\/\/CRAN.R-project.org\/package=SuperLearner (2022)."},{"key":"55931_CR47","doi-asserted-by":"crossref","unstructured":"Polley, E. C. & van der Laan, M. J. Super Learner in Prediction Working Paper Series. Paper 226. http:\/\/biostats.bepress.com\/ucbbiostat\/paper266\/ (UC Berkeley Division of Biostatistics, 2010).","DOI":"10.32614\/CRAN.package.SuperLearner"},{"key":"55931_CR48","doi-asserted-by":"crossref","unstructured":"Kenny, A. Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data. PhD dissertation, Department of Biostatistics, University of Washington (2023).","DOI":"10.32614\/CRAN.package.vaccine"},{"key":"55931_CR49","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/biostatistics\/kxac024","volume":"24","author":"PB Gilbert","year":"2023","unstructured":"Gilbert, P. B., Fong, Y., Kenny, A. & Carone, M. A controlled effects approach to assessing immune correlates of protection. Biostatistics 24, 850\u2013865 (2023).","journal-title":"Biostatistics"},{"key":"55931_CR50","unstructured":"Kenny, A. vaccine. Tools for analysis of vaccine clinical trial data. https:\/\/github.com\/Avi-Kenny\/vaccine (2024)."},{"key":"55931_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03154-6","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 11, 23921 (2021).","journal-title":"Sci. Rep."},{"key":"55931_CR52","doi-asserted-by":"publisher","unstructured":"Fong, Y. et al. Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Zenodo https:\/\/doi.org\/10.5281\/zenodo.14324535 (2024).","DOI":"10.5281\/zenodo.14324535"},{"key":"55931_CR53","unstructured":"R. Core Team. R: A Language and Environment for Statistical Computing https:\/\/www.R-project.org (R Foundation for Statistical Computing; Vienna, Austria, 2023)."},{"key":"55931_CR54","doi-asserted-by":"crossref","unstructured":"Kenny, A. vaccine: statistical tools for immune correlates analysis of vaccine clinical trial data. R package version 1.2.1 https:\/\/CRAN.R-project.org\/package=vaccine (2024).","DOI":"10.32614\/CRAN.package.vaccine"},{"key":"55931_CR55","unstructured":"Westling, T. CFsurvival. R package for nonparametric estimation of counterfactual survival functions and survival contrasts from right-censored data with an observational baseline treatment. https:\/\/github.com\/tedwestling\/CFsurvival\/ (2023)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55931-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55931-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:54:00Z","timestamp":1737086040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-55931-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55931"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-55931-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.G.R. is a paid safety consultant for ICON, CyanVac, Imunon, and EMMES, and has served on selected advisory boards for Sanofi, Seqirus, Pfizer-BioNTech and Moderna. Emory receives funds for N.G.R. to conduct research from Sanofi, Lilly, Merck, Quidel, Immorna, Vaccine Company, and Pfizer-BioNTech. S.K. reports research support to his institution from Pfizer-BioNTech, Moderna, Bavarian Nordic, Meissa, Centers for Disease Control and Prevention, and National Institutes of Health. E.B.W. has served as an investigator for clinical trials or studies sponsored by Pfizer-BioNTech, Moderna, Seqirus, Najit, and Clinetic; on advisory boards for Pfizer-BioNTech and Vaxcyte; as a consultant to IliAD Biotechnologies; and as a DSMB member for Shionogi. T.M.B. has served on an Advisory Board for Sanofi. D.N.F. has served on an Advisory Board for Gilead Sciences and for AXCELLA, and as site PI for clinical trials sponsored by Gilead Sciences, Regeneron, MetroBiotech LLC, and the NIH (DMID COVAIL). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"759"}}